Natural killer (NK) cells play a major role in cancer immunotherapies that involve tumor-
antigen targeting by monoclonal antibodies (mAbs). NK cells express a variety of activating …

With steadily improved cure rates for children with newly diagnosed acute lymphoblastic
leukaemia (ALL), treating relapsed ALL has become increasingly challenging largely due to …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …

Background Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate
disease control with rituximab-based treatment have few treatment options and a poor …

We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a
novel glycoengineered type II CD20 monoclonal antibody, with rituximab and ofatumumab …

Increasing the remission rate and reducing the recurrence rate can improve the clinical
efficacy of chimeric antigen receptor (CAR) T cell therapy in recurrent/refractory non …

Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy
of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to …

Therapeutic monoclonal antibodies (mAbs) that target the CD20 antigen on B cells are
successfully used in the clinic for the depletion of B cells to treat various forms of cancer and …

While rituximab has dramatically improved outcomes for patients with CD20+ malignancies
for two decades, responses are not universal and resistance can develop. Obinutuzumab …

Obinutuzumab (GA101) is a glycoengineered type 2 CD20 antibody with enhanced CD16A-
binding and natural killer–mediated cytotoxicity. CD16B is highly homologous to CD16A and …